On October 5, 2021, T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, announced that they are entering a collaborative agreement with Atlas Antibodies for the development, manufacture, and supply of CT83 (KK-LC-1) monoclonal antibodies.
These will be used to develop a diagnostic test to identify tumors that express CT83. As a result, patients with CT83 positive tumors may be eligible for inclusion in CT83 targeted T-Cell therapy clinical trials.
Under the agreement terms, Atlas Antibodies will provide all manufacturing and product supply for CT83 (KK-LC-1) monoclonal antibody (mAb) for the companion diagnostic for clinical development.
T-Cure is developing a T Cell Receptor Gene Therapy TCR-T targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple-negative breast cancer, cervical, lung, and other KK-LC-1 positive epithelial cancers.
T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsor clinical trial planned for 2022.
Read the press release